NCT05208112 - Intravenously Administered M6229 in Critically Ill Sepsis Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 5, 2022

Primary Completion Date

September 28, 2023

Study Completion Date

September 28, 2023

Conditions

SepsisSeptic ShockCritical Illness

Interventions

DRUG

M6229

Continuous intravenous infusion of M6229, a low-anticoagulant fraction of heparin. Dose-escalation is based on a modified continual reassessment method (mCRM) including escalation with overdose control (EWOC).

Trial Locations (2)

6229HX

Maastricht UMC+, Maastricht

1105AZ

Amsterdam UMC, location AMC, Amsterdam